| ID | 1160 |
| Name of the vaccine | Vaxem Hib |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 2 months and older |
| Description of the vaccine | Haemophilus influenzae type b conjugate vaccine. |
| Name of the manufacturer | Novartis Vaccines & Diagnostics S.r.l and GlaxoSmithKline |
| Name of the manufacturing country | Italy |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Colourless white opalescent liquid |
| Dosage | Primary Series-
Under 13 months : Three 0.5ml doses, gap of 4 weeks.
13 months and greater : Single 0.5 mL dose.
Booster- If 3 doses given before the age of 6 months, additional fourth dose should be given. |
| Mechanism of action | Antigenic capsular polysaccharides induce Ab production. |
| Route of administration | Intramuscular |
| Indications | Not recommended for healthy children greater than 4 years. |
| Export | Takeda, Japan (2009) and GlaxoSmithKline (2015) |
| Approval | NA |
| Adjuvant | Aluminium phosphate |
| Repurposing | NA |
| Side effects of vaccine | Infants 2 to 6 months: tenderness, erythema, induration, unusual crying, irritability, vomiting, diarrhoea, change in eating habits, sleepiness, fever.
Children 12 to 15 months: unusual crying, irritability, vomiting, diarrhoea, change in eating habits, sleepiness, fever.
Booster in children 16 to 20 months: irritability |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.who.int/immunization_standards/vaccine_quality/VaxemHib_product_insert.pdf |
| Other name | NA |
| Additional Links | NA
|